May 30 – June 1, 2023 | Boston, MA

With 3 jam-packed days of content across CAR-, TCR– and polyclonal Tregs as well as IL-2, muteins and small molecules, don’t miss this opportunity to collaborate with your peers in the Treg field to explore clinical advances, discuss challenges and discover next-gen methods to take Treg therapies to the next level.

Outlining the landscape and highlighting the opportunities within the Treg field, is Beacon’s own Immune Tolerance Research Analyst, Thomas Hall, so there’s one to mark on your agenda not to miss!

Recognize therapy efficacy, determine safety, and translate the next generation of therapies into the clinic today